Developing successful medicines depends on picking the right target and product profile based on the disease biology of your patients.
We enable you to achieve this by identifying causal druggable genes and stratifying patient populations at an unprecedented level of resolution – uncovering patient subgroups with distinct disease etiologies to find new targets for therapeutic intervention.
In-license novel targets for drug discovery and potential drug repositioning opportunities, with full data packages
Understand the link between dysregulated biological pathways and multiple disease indications
License biomarkers to select patients for clinical trials and as complementary diagnostic tools to support product launch
We resolve complex chronic diseases which often appear untreatable because the current clinical ontologies do not distinguish between a mixture of underlying causes.
Our high-resolution patient stratification reveals previously unrecognized disease mechanisms which bring with them new targets for drug discovery and opportunities for first-in-class medicines.
Our patient stratification provides biomarkers for the selection of highly relevant translational disease models, in patient selection for clinical trials, and in the design of companion diagnostics.
To ensure the right targets are selected, we apply proven drug discovery evaluation frameworks, such as the 5Rs criteria for small molecules1, and extend them to include the selection of targets with the right efficacy potential to minimize late-stage failure risks in downstream clinical trials.
1. Morgan, P. et al. (2018) Impact of a five-dimensional framework on R&D productivity at AstraZeneca, Nature Reviews Drug Disc. 17, 167-181
Our Innovation Engine enables a precision medicine approach to complex diseases – uniquely matching targets to patients with an underlying biological cause that will respond to a new treatment.
We integrate all forms of large datasets to rapidly provide links to new areas of biology and potential new therapeutic targets.
And our stratification of patient groups identifies biomarkers that accurately match your treatment to responders in both trials and the clinic.
For the first time, our approach was able to stratify ALS patients into clinically relevant subgroups based on their genetic differences and identify novel druggable targets with genetic linkage to the stratified patient subgroups.
